Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Neoplasms 3Stomach Neoplasms 1Solid Tumor 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 29Carboplatin 25Topotecan 12Gemcitabine 11Cyclophosphamide 11Cisplatin 11Taxes 10Filgrastim 9sargramostim 8pembrolizumab 8Docetaxel 8Bevacizumab 8Peripheral Blood Stem Cell Transplantation 6liposomal doxorubicin 5Flow Cytometry 5Interleukin-12 Subunit p35 4Drug Therapy 4fludarabine phosphate 3fludarabine 3Sirolimus 3Nivolumab 3Melphalan 3Immunohistochemistry 3Immunoenzyme Techniques 3Granulocyte-Macrophage Colony-Stimulating Factor 3Fulvestrant 3Etoposide 3Chemotherapy, Adjuvant 3Capecitabine 31-dodecylpyridoxal 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Ovarian Epithelial × saracatinib × Clear all
NCT01000896 2010-02-04

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

AstraZeneca

Phase 1 Withdrawn
27 enrolled
GynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡